IPhA HOD

Special Session 2018

Information

Background

The Illinois Pharmacists Association has a policy on Medical Marijuana from 2011. The public views surrounding Medical Marijuana and various state policies have changed since that time. With a new Governor Elect pushing for expanding the use of marijuana and the federal government looking to make some policy changes to allow increased access to marijuana we need a stronger and more time sensitive policy to be prepared for new opportunities in the profession of pharmacy. specifically we should consider if we want to promote pharmacist involvement with the possible expansion of marijuana use in Illinois.

Current Policy

Medical Marijuana – 2011

IPhA supports research by properly qualified investigators operating under the investigational new drug (IND) process to explore fully the potential medicinal uses of marijuana and its constituents or derivatives.

IPhA urges the DEA to change marijuana’s status as a federal Schedule I controlled substance to Schedule II; with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods.

IPhA supports that when such evidence exists, pharmacists be the only mechanism in which this medication can be distributed to patients in the same legislative manner that they currently distribute controlled medications.

IPhA supports pharmacists’ involvement in dispensing standardized medical marijuana if provided within the context of appropriately structured clinical trials or protocols and that medical marijuana should be regulated by good manufacturing practices to ensure quality, safety and standardizations of the drug.

This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product.


APhA Policy 2014-2015

Role of the Pharmacist in the Care of Patients Using Cannabis (As Originally Proposed)

The Committee recommends that the Association adopt the following statements:

1. APhA advocates for resolution of the federal and state conflicts surrounding the legal status of cannabis and its various components.

2. APhA supports the establishment of a USP monograph for the standardization of cannabis and its various components.

3. APhA supports regulatory changes to facilitate clinical research related to the clinical efficacy and safety associated with the use of cannabis and its various components.

4. APhA encourages health care provider education related to the clinical efficacy, safety, and management of patients using cannabis and its various components.

5. APhA advocates that the pharmacist collect and document information in the pharmacy patient profile about patient use of cannabis and its various components and provide appropriate patient counseling.

6. APhA supports pharmacist participation in furnishing cannabis and its various components when scientific data support the legitimate medical use of the products and delivery mechanisms and federal, state, or territory laws or regulations permit pharmacists to furnish them.

7. APhA opposes the furnishing of cannabis and its various components for medical purposes unless performed by licensed health care professionals whose scope of practice includes the dispensing of prescription medications and who comply with state and federal regulations.

8. APhA supports the clinical judgment of pharmacists to decide whether to furnish cannabis and its various components for medical use where allowed by law.

9. APhA opposes pharmacist involvement in furnishing cannabis and its various components for recreational use.


Role of the Pharmacist in the Care of Patients Using Cannabis (Policy Enacted by the APhA House of Delegates)

2015

1. APhA supports regulatory changes to further facilitate clinical research related to the clinical efficacy and safety associated with the use of cannabis and its various components.

2. APhA encourages health care provider education related to the clinical efficacy, safety, and management of patients using cannabis and its various components.

3. APhA advocates that the pharmacist collect and document information in the pharmacy patient profile about patient use of cannabis and its various components and provide appropriate patient counseling.

4. APhA supports pharmacist participation in furnishing cannabis and its various components when scientific data support the legitimate medical use of the products and delivery mechanisms, and federal, state, or territory laws or regulations permit pharmacists to furnish them.

5. APhA opposes pharmacist involvement in furnishing cannabis and its various components for recreational use.

Topic: Public Health

(JAPhA N55(4): 365 July/August 2015)